Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.
Earnings per share decreased 60.43% year over year to ($2.23), which may not compared to the estimate of ($1.36).
Revenue of $1,549,000 higher by 171.75% from the same period last year, which beat the estimate of $1,030,000.
Albireo Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 07, 2020
Webcast URL: http://public.viavid.com/player/index.php?id=138368
Recent Stock Performance
Company's 52-week high was at $38.69
52-week low: $11.26
Price action over last quarter: Up 3.09%
Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.